Recent Company News

• 03:20 AM ET Dec 05, 2025
  

  Shanghai Pharmaceuticals terminates X842 production, development and sales agreement with Shengnuo Biotechnology (HK$12.16, 0.00)

• 08:44 PM ET Nov 05, 2025
  

  StreetAccount Sector Summary - China Healthcare October Recap

• 05:39 AM ET Oct 30, 2025
  

  Shanghai Pharmaceuticals Holding declares H1 interim dividend CNY0.12/share vs year-ago CNY0.08/share (HK$12.34, 0.00)

• 05:36 AM ET Oct 30, 2025
  

  Shanghai Pharmaceuticals Holding reports Q3 CAS net income attributable CNY688.2M, (38.1%) y/y (HK$12.34, 0.00)

• 03:23 AM ET Oct 06, 2025
  

  StreetAccount Sector Summary - China Healthcare September Recap

• 10:55 AM ET Sep 15, 2025
  

  Bristol Myers Squibb confirms agreement to sell entire 60% stake in Sino-American Shanghai Squibb Pharmaceuticals - China Business News

• 04:48 AM ET Sep 08, 2025
  

  Shanghai Pharmaceuticals Holding completes acquisition of additional 10% stake in Shanghai Industrial Investment Group Finance (HK$12.19, 0.00)

• 04:14 AM ET Aug 28, 2025
  

  Shanghai Pharmaceuticals Holding reports H1 net income attributable CNY4.46B vs guidance CNY4.45B and year-ago CNY2.94B

• 05:26 AM ET Aug 08, 2025
  

  NMPA approves Shandong Boan Biotechnology's Boyouping for glycemic control in adults with type 2 diabetes (HK$18.40, 0.00)

• 05:48 AM ET Aug 01, 2025
  

  StreetAccount Sector Summary - China Healthcare July Recap